Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-26 am EDT			5-day change	1st Jan Change
545.5 ^INR	+2.86%		+2.05%	+65.10%

Apr. 18	Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	MT
Apr. 17	Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	MT

Shilpa Medicare Limited, Unit III R&D Facility Clears US FDA Remote Record Review with No Observations

November 19, 2021 at 01:22 am EST

Shilpa Medicare Limited announced that US FDA has concluded Remote Record Review of, Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th November 2021.

Latest news about Shilpa Medicare Limited

Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	Apr. 18	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	Apr. 17	MT
Shilpa Medicare Gets Board Nod to Launch QIP	Apr. 09	MT
Shilpa Medicare's Life Science Arm Names CEO	Mar. 28	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	Mar. 01	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	Feb. 26	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	Feb. 12
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	Jan. 19	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	Nov. 02	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	23-10-11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	23-09-04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	23-09-04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	23-09-01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	23-08-25	MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023	23-08-11
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries	23-08-08	CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections	23-07-31	MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India	23-06-29	CI
Shilpa Medicare to Raise Up to INR3.25 Billion from Rights Issue	23-06-23	MT
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA	23-05-23	CI
Shilpa Medicare Limited Announces US FDA GMP Inspection Cleared with VAI Classification	23-05-22	CI

Chart Shilpa Medicare Limited

Duration

Period

More charts

Company Profile

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+65.10%	553M
ELI LILLY AND COMPANY	+26.11%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.47%	354B
MERCK & CO., INC.	+20.14%	331B
ABBVIE INC.	+3.85%	296B
ASTRAZENECA PLC	+12.88%	233B
NOVARTIS AG	+5.59%	201B
ROCHE HOLDING AG	-9.65%	193B
AMGEN INC.	-6.30%	144B

Other Pharmaceuticals